Tenon Medical, Inc. (TNON)

Several events have impacted TENON Medical, Inc.'s stock price in the past six months. On March 19, 2026, the company reported record revenue growth and improved gross margins for the fourth quarter and full-year 2025. On March 12, 2026, TENON Medical announced the closing of a private placement of senior convertible notes, raising $4.3 million. On February 25, 2026, the company received a letter from Nasdaq indicating that its common stock had not maintained the minimum bid price. On January 28, 2026, TENON Medical issued a shareholder letter highlighting preliminary revenue figures, the acquisition of SiVantage assets, and FDA clearance for an expanded indication for the Catamaran SI Joint Fusion System. The merger/acquisition with SiVantage occurred on August 1, 2025.

Direct information regarding demand seasonality for TENON Medical, Inc.'s products and services is not explicitly available. Historical stock price data suggests some seasonality in investor returns, with October historically showing the highest probability of positive returns, while May may not be an ideal month for investment. Significant seasonal fluctuations in product demand are not typically expected for medical devices for chronic conditions.

TENON Medical, Inc. is a medical device company specializing in minimally invasive surgical implant systems for sacroiliac (SI) joint and sacro-pelvic disorders. Their primary product is the Catamaran SI Joint Fusion System, which uses a titanium implant to stabilize the SI joint. They also offer the SImmetry+ SI-Joint Fusion System. The company focuses on primary SI joint procedures, revision procedures, and adjunct fixation to spinal fusion constructs.

TENON Medical, Inc. primarily focuses its commercial activities on the U.S. market and Puerto Rico. While the company has a Swiss subsidiary, profitability is reported on a consolidated basis without geographic segmentation.

TENON Medical's brand reputation has a "Hold" rating from Danelfin's AI model, with a slightly favorable outlook. MarketBeat's news sentiment tracking indicates an average news sentiment score of 0.00 for TNON, compared to an average of 0.45 for medical news. The Nasdaq letter regarding the minimum bid price requirement could negatively impact the company's reputation.

TENON Medical, Inc. has 18 institutional owners and shareholders holding a total of 429,485 shares. Major institutional owners include Vanguard Group Inc, DRW Securities, LLC, Geode Capital Management, Llc, SBI Securities Co., Ltd., Citadel Advisors Llc, Northern Trust Corp, XTX Topco Ltd, Virtu Financial LLC, Two Sigma Securities, Llc, Spectrum Asset Management, Inc. (NB/CA), Jane Street Group LLC, Renaissance Technologies LLC, Clear Street Group, Inc., and Heights Capital Management, Inc. Institutional investors collectively own between 22.74% and 39.0% of the company's stock. Individual insiders hold 7.03% of the shares, while the general public owns 85.4%.